File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Hepatocellular carcinoma in the Asia pacific region
  • Basic View
  • Metadata View
  • XML View
TitleHepatocellular carcinoma in the Asia pacific region
 
AuthorsYuen, MF3
Hou, JL1
Chutaputti, A2
 
Issue Date2009
 
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
 
CitationJournal Of Gastroenterology And Hepatology, 2009, v. 24 n. 3, p. 346-353 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1746.2009.05784.x
 
AbstractPrimary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide. It is among the top three causes of cancer death in the Asia Pacific region because of the high prevalence of its main etiological agents, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. In this region, the incidence of HCC has been static over recent decades. Older age is a major risk factor; the incidence increasing sharply after age 40 years. There is a male predilection, with male to female ratio of 3:1, except in elderly Japanese with equal sex incidence or female predominance. In most Asia-Pacific countries, chronic HBV infection accounts for 75-80% of cases; Japan, Singapore and Australia/New Zealand are exceptions because of higher prevalence of HCV infection. In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis ('lead-time bias'). The majority of patients present with advanced diseases, hence reducing the chance of curative treatment. The importance of HCC may decrease in two to three decades when the prevalence of chronic HBV infection decreases as a result of the universal HBV vaccination programs implemented in late 1980s in most Asia-Pacific countries, and because of reduced incidence of medical transmission of HCV. However, transmission of HCV by injection drug use, and rising prevalence of obesity and diabetes, both independent risk factors for HCC, may partly offset this decline. © 2009 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
 
ISSN0815-9319
2012 Impact Factor: 3.325
2012 SCImago Journal Rankings: 0.985
 
DOIhttp://dx.doi.org/10.1111/j.1440-1746.2009.05784.x
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYuen, MF
 
dc.contributor.authorHou, JL
 
dc.contributor.authorChutaputti, A
 
dc.date.accessioned2012-09-05T05:29:02Z
 
dc.date.available2012-09-05T05:29:02Z
 
dc.date.issued2009
 
dc.description.abstractPrimary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide. It is among the top three causes of cancer death in the Asia Pacific region because of the high prevalence of its main etiological agents, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. In this region, the incidence of HCC has been static over recent decades. Older age is a major risk factor; the incidence increasing sharply after age 40 years. There is a male predilection, with male to female ratio of 3:1, except in elderly Japanese with equal sex incidence or female predominance. In most Asia-Pacific countries, chronic HBV infection accounts for 75-80% of cases; Japan, Singapore and Australia/New Zealand are exceptions because of higher prevalence of HCV infection. In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis ('lead-time bias'). The majority of patients present with advanced diseases, hence reducing the chance of curative treatment. The importance of HCC may decrease in two to three decades when the prevalence of chronic HBV infection decreases as a result of the universal HBV vaccination programs implemented in late 1980s in most Asia-Pacific countries, and because of reduced incidence of medical transmission of HCV. However, transmission of HCV by injection drug use, and rising prevalence of obesity and diabetes, both independent risk factors for HCC, may partly offset this decline. © 2009 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
 
dc.description.natureLink_to_OA_fulltext
 
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2009, v. 24 n. 3, p. 346-353 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1746.2009.05784.x
 
dc.identifier.citeulike4244725
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1440-1746.2009.05784.x
 
dc.identifier.epage353
 
dc.identifier.hkuros161055
 
dc.identifier.issn0815-9319
2012 Impact Factor: 3.325
2012 SCImago Journal Rankings: 0.985
 
dc.identifier.issue3
 
dc.identifier.pmid19220670
 
dc.identifier.scopuseid_2-s2.0-63049111543
 
dc.identifier.spage346
 
dc.identifier.urihttp://hdl.handle.net/10722/163238
 
dc.identifier.volume24
 
dc.languageeng
 
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
 
dc.publisher.placeAustralia
 
dc.relation.ispartofJournal of Gastroenterology and Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAge Factors
 
dc.subject.meshAsia - Epidemiology
 
dc.subject.meshAsian Continental Ancestry Group
 
dc.subject.meshCarcinoma, Hepatocellular - Epidemiology - Ethnology - Etiology - Mortality - Therapy
 
dc.subject.meshFemale
 
dc.subject.meshHepatitis B, Chronic - Complications - Epidemiology
 
dc.subject.meshHepatitis C, Chronic - Complications - Epidemiology
 
dc.subject.meshHumans
 
dc.subject.meshIncidence
 
dc.subject.meshLiver Neoplasms - Epidemiology - Ethnology - Etiology - Mortality - Therapy
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshOdds Ratio
 
dc.subject.meshPrevalence
 
dc.subject.meshPrognosis
 
dc.subject.meshRisk Assessment
 
dc.subject.meshRisk Factors
 
dc.subject.meshSex Factors
 
dc.titleHepatocellular carcinoma in the Asia pacific region
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yuen, MF</contributor.author>
<contributor.author>Hou, JL</contributor.author>
<contributor.author>Chutaputti, A</contributor.author>
<date.accessioned>2012-09-05T05:29:02Z</date.accessioned>
<date.available>2012-09-05T05:29:02Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Journal Of Gastroenterology And Hepatology, 2009, v. 24 n. 3, p. 346-353</identifier.citation>
<identifier.issn>0815-9319</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163238</identifier.uri>
<description.abstract>Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide. It is among the top three causes of cancer death in the Asia Pacific region because of the high prevalence of its main etiological agents, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. In this region, the incidence of HCC has been static over recent decades. Older age is a major risk factor; the incidence increasing sharply after age 40 years. There is a male predilection, with male to female ratio of 3:1, except in elderly Japanese with equal sex incidence or female predominance. In most Asia-Pacific countries, chronic HBV infection accounts for 75-80% of cases; Japan, Singapore and Australia/New Zealand are exceptions because of higher prevalence of HCV infection. In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis (&apos;lead-time bias&apos;). The majority of patients present with advanced diseases, hence reducing the chance of curative treatment. The importance of HCC may decrease in two to three decades when the prevalence of chronic HBV infection decreases as a result of the universal HBV vaccination programs implemented in late 1980s in most Asia-Pacific countries, and because of reduced incidence of medical transmission of HCV. However, transmission of HCV by injection drug use, and rising prevalence of obesity and diabetes, both independent risk factors for HCC, may partly offset this decline. &#169; 2009 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.</description.abstract>
<language>eng</language>
<publisher>Wiley-Blackwell Publishing Asia. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/JGH</publisher>
<relation.ispartof>Journal of Gastroenterology and Hepatology</relation.ispartof>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Age Factors</subject.mesh>
<subject.mesh>Asia - Epidemiology</subject.mesh>
<subject.mesh>Asian Continental Ancestry Group</subject.mesh>
<subject.mesh>Carcinoma, Hepatocellular - Epidemiology - Ethnology - Etiology - Mortality - Therapy</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - Complications - Epidemiology</subject.mesh>
<subject.mesh>Hepatitis C, Chronic - Complications - Epidemiology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Incidence</subject.mesh>
<subject.mesh>Liver Neoplasms - Epidemiology - Ethnology - Etiology - Mortality - Therapy</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Odds Ratio</subject.mesh>
<subject.mesh>Prevalence</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Risk Assessment</subject.mesh>
<subject.mesh>Risk Factors</subject.mesh>
<subject.mesh>Sex Factors</subject.mesh>
<title>Hepatocellular carcinoma in the Asia pacific region</title>
<type>Article</type>
<description.nature>Link_to_OA_fulltext</description.nature>
<identifier.doi>10.1111/j.1440-1746.2009.05784.x</identifier.doi>
<identifier.pmid>19220670</identifier.pmid>
<identifier.scopus>eid_2-s2.0-63049111543</identifier.scopus>
<identifier.hkuros>161055</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-63049111543&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>24</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>346</identifier.spage>
<identifier.epage>353</identifier.epage>
<publisher.place>Australia</publisher.place>
<identifier.citeulike>4244725</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/163238/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. Nanfang Hospital
  2. Phramongkutklao Hospital
  3. The University of Hong Kong